Our partner is focused on developing innovative antibody-drug conjugates (ADCs) for cancer treatment. Their approach aims to deliver potent therapies directly to tumors, improving treatment efficacy while minimizing side effects, with the goal of enhancing patient outcomes in oncology.

This hire built the regulatory CMC function and was a critical member of the regulatory leadership team. They helped advance assets from early to late stages of development and through major regulatory submissions to commercialization.